ALDX
Aldeyra Therapeutics, Inc.
0.9159$
-0.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -75.1% | -100.0% | – | – | -65.6% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.7% | +2.5% | -10.4% | +2.4% | +2.0% | +2.0% | +2.0% | +0.5% | -3.9% | +1.0% | +2.3% | -8.8% | +1.6% | +2.2% | +2.2% | -5.4% | +2.2% | +2.2% | +2.2% | +2.3% | – | – | |
| – | – | -75.1% | -100.0% | – | – | -65.6% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.0% | -2.3% | +14.2% | -8.0% | +56.7% | +19.0% | +2.9% | +16.0% | +8.5% | -8.2% | +35.9% | +52.1% | -40.7% | -31.0% | -26.3% | +25.5% | +14.6% | +9.9% | +48.5% | +12.4% | -0.4% | -4.7% | +19.1% | -20.8% | -22.3% | +25.4% | -38.0% | 0.0% | -38.3% | +43.9% | +142.1% | -16.9% | +17.6% | -49.3% | +14.6% | -36.1% | -20.8% | -44.0% | +44.6% | – | |
| – | -13.7% | +43.2% | -14.2% | -0.4% | +1.7% | +26.0% | +25.5% | +29.2% | -17.0% | +17.2% | +4.4% | -8.9% | +13.2% | -6.5% | -26.1% | +1.6% | +11.1% | +23.9% | -1.2% | -17.0% | +0.6% | +65.8% | -26.0% | +3.2% | +45.9% | +17.6% | -39.3% | -23.4% | -30.5% | +78.4% | -5.4% | +21.7% | -47.3% | +54.2% | -44.6% | +54.5% | -8.0% | +48,103,998.5% | -100.0% | – | |
| – | -2.6% | +9.5% | +4.6% | -5.9% | +40.5% | +20.5% | +7.9% | +19.4% | +1.4% | +57.1% | -21.2% | +38.5% | -32.2% | -25.3% | -26.3% | +18.1% | +34.5% | -4.0% | +34.3% | +6.2% | -0.2% | +7.0% | +7.5% | -16.5% | -7.4% | +22.7% | -38.4% | -7.7% | -36.2% | +54.1% | +91.7% | -10.4% | +2.7% | -37.1% | -2.5% | -21.3% | -16.7% | -47.8% | +68.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -2.5% | +3.2% | -1.4% | +4.2% | +18.1% | -13.9% | -6.0% | +9.4% | +120.3% | -96.9% | +1,360.2% | +1.8% | +1,766.2% | -19.2% | +10.5% | +0.6% | 0.0% | -1.3% | -10.2% | -4.7% | 0.0% | -1.7% | +1.1% | +1.6% | +10.5% | +6.6% | +7.3% | +2.2% | -4.5% | -3.1% | -4.2% | +0.3% | -1.8% | +2.7% | -2.7% | +1.1% | -0.1% | -1.4% | -100.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.8% | +14.7% | +53.0% | +17.1% | +119.9% | -10.9% | +27.9% | +14.8% | +222.3% | -349.4% | – | +529.9% | -4,493,282,977.1% | – | -65.9% | -92.7% | -9,290.1% | – | +66.9% | +49.5% | +596.3% | -26.2% | -78.3% | -449.9% | – | – | – | +1.0% | -262.4% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.